SHG · Clinical Research Centre/Lung Cancer CDR (Pilot)
CR
Pilot environment — synthetic demographics; real de-identified pathology sample (n=62; +80 synthetic; total 142).
Discovery

Cohort Search

Build patient cohorts by combining clinical criteria — or describe what you need in plain language.

Define Cohort Criteria

142 patients in repository (62 real · 80 mock)
142 of 142 patients match
Open in Assistant
PatientCohortHPEStageMutationsTumorSUVCEAPD-L1Best Resp.Outcome
Patient #001RealAdenocarcinomaIIIB (T2b,N3)
EGFR L858R
4.113.21NA (Scheduled 16 Mar 2026)——Disease-free
Patient #002RealAdenocarcinoma: AcinarIA2 (T1b, N0)
EGFR L858R
29.995——Disease-free
Patient #003RealAdenocarcinoma: AcinarIIA (T2b, N0)
EGFR Exon 19 Del
4.22.755.6——Disease-free
Patient #004RealAdenocarcinomaIA3
EGFR L858R
2.31.273——Stable
Patient #005RealAdenocarcinoma: LepidicIA3 (T1c, N0)
EGFR Exon 19 Del
2.16.553.7——Stable
Patient #006RealAdenocarcinoma: AcinarIA2
EGFR Exon 19 DelTP53PTEN
1.3NA1.9——Watchful Wait
Patient #007RealTuberculosisIIB (T1b, N1)
Not tested
1.58.61.8——N/A
Patient #008RealAdenocarcinoma: AcinarIA3 (T1c, N0)
EGFR L858R
2.16.62.2——Disease-free
Patient #009RealAdenocarcinoma: AcinarIIA (T2b, N0)
EGFR Exon 19 DelTP53
4.613.7211.4——Disease-free
Patient #010RealGranulomatous tuberculosisInflammatory
Not tested
2.25.273.4——N/A
Patient #011RealAdenocarcinoma: Moderately differentiatedIA2 (T1b, N0)
ALK fusionTP53
1.391.6——Stable
Patient #012RealDense lymphocytic infiltration with clusters of atypical cellsNA
Not tested
1.62.621.6——N/A
Patient #013RealAdenocarcinoma: LepidicIA3 (T1c, N0)
EGFR Exon 19 Del
2.42.7910.2——Progression
Patient #014RealAdenocarcinoma: Lepidic and PapillaryIA2 (T1b, N0)
EGFR Exon 19 Del
1.82.681.4——Stable
Patient #015RealAdenocarcinoma: AcinarIA3 (T1c, N0)
KRAS Q61HTP53
2.72.858.2——Stable
Patient #016RealAdenocarcinoma: NOSIA3 (T1c, N0)
No mutations
2.32.4820.5——Disease-free
Patient #017RealAdenocarcinoma: LepidicIA1 (T1a, N0)
Not tested
2.2NA2.1——Disease-free
Patient #018RealAdenocarcinoma: AcinarIB (T2a, N0)
No mutations
42.851——Stable
Patient #019RealAdenocarcinoma: bronchioalveolar carcinomaIB (T2a, N0)
KRAS G12V
3.44.130.9——Disease-free
Patient #020RealNET - TYPICAL CARCINOIDIA2 (T1b, N0)
No mutations
1.86.351.1——Stable
Patient #021RealAdenocarcinoma: AcinarIIB (T3, N0)
KRAS G12VTP53
763.3——Disease-free
Patient #022RealAdenocarcinoma: AcinarIA2 (T1b, N0)
EGFR Exon 19 DelTP53
1.51.89NA——Disease-free
Patient #023RealAdenocarcinoma: PapillaryIA3 (T1c, N0)
EGFR Exon 19 Del
2.97.061.2——Disease-free
Patient #024RealAdenocarcinomaIIB (T3, N0)
No mutations
5.16.491.9——Progression
Patient #025RealAdenocarcinomaIA3 (T1c, N0)
ERBB2 Exon 20
2.29.152.6——Watchful Wait
Patient #026RealAdenocarcinomaIIIA (T4, N0)
KRAS
12NANA——Stable
Patient #027RealFrozen section shows necrotizing granulomatous inflammation with background fibrosis, negative for malignancyNA
Not tested
29.6NA——N/A
Patient #028RealNo granuloma, atypical cells or malignancy is seenNA
Not tested
1.51.991.3——N/A
Patient #029RealStage 1A2, pT1b, N0, well-differentiated lung adenocarcinoma, ERBB2 positive (exon 20 insertion)IA2 (T1b, N0)
ERBB2 Exon 20
1.43.332.3——Stable
Patient #030RealT1c N0 M0, well-differentiated carcinoid tumorNA
Not tested
2.419.642.2——Disease-free
Patient #031RealPoorly differentiated adenocarcinomaIIIA (T1c, N2)
No mutations
2.29.738.2——Disease-free
Patient #032RealModerately differentiated adenocarcinoma, stage IIIA (T2b, N2, Mx), no mutations (2x testing)IIIA (T2a, N2)
No mutations
3.78.17380——Disease-free
Patient #033RealWell differentiated lepidic adenocarcinoma, stage 1A3, p1c, N0IA3 (T1c, N0)
Not tested
2.52.247.1——Disease-free
Patient #034RealPoorly differentiated adenocarcinomaIVB (T4, N3, M1c)
ALK fusion
8.710.77NA——Stable
Patient #035RealModerately differentiated primary adenocarcinoma, acinarIIA (T2b, N0)
EGFR L858RPIK3CA
4.68.681.8——Stable
Patient #036RealAdenoid cystic carcinoma, stage IB (T2a, N0, Mx), LV, VP invasion, no STASIB (T2a, N0)
Not tested
2.77.42.3——Watchful Wait
Patient #037RealInvasive, poorly differentiated NSCLC adenocarcinoma, EGFR (Exon 20, insertion), TP53 (H193R mutation)IIIB (T3, N2b, M0) Post peri-operative chemo + IO = IB (T2a, N0)
EGFR Exon 20 InsTP53
5.213.0528.4——Stable
Patient #038RealModerately differentiated adenocarcinoma, mainly acinar and partly lepidic, LVI, STATS present, T2a EGFR L861Q positive, TP53 co-mutationIIIA (T2a, N2a)
EGFR L861QTP53
3.88.49.9——Disease-free
Patient #039RealAdenocarcinoma, IA3 (T1c, N0, Mx), EGFR (L858R mutation)IA3 (T1c, N0)
EGFR L858R
313.11——Disease-free
Patient #040RealPoorly differentiated adenocarcinoma, stage IIIA (T2a, N2a, Mx), acinar, STATS presentIIIA (T2a, N2b)
EGFR L858RTP53
3.415.322.5——Stable
Patient #041RealWell-differentiated adenocarcinoma, acinar, no invasion, stage IA (T1b, N0, Mx)IA2 (T1b, N0)
KRAS G12C
204.2——Disease-free
Patient #042RealPoorly differentiated adenocarcinoma, stage IIB (T1c, N2a, Mx)IIB (T1c, N2a, Mx)
No mutations
2.54.8123——Disease-free
Patient #043RealFeatures from frozen section are consistent with focal pneumonia, no granuloma, atypical cells or malignancy is seenNA
Not tested
1.50Normal——N/A
Patient #044RealAdenosquamous carcinoma, predominant moderately differentiated squamous cell carcinoma, no LVI, no STATS, stage IB (T2a, N0, Mx)IB (T2a, N0)
EGFR L858RTP53
3.510.144.5——Watchful Wait
Patient #045RealWell-differentiated adenocarcinoma, acinar and papillary patterns, no LVI, no STATS, stage IA2 (T1b, N0, Mx)IA2 (T1b, N0)
ALK fusion
1.83.841.2——Stable
Patient #046RealUndifferentiated large cell malignancy in the lung, differential diagnoses include poorly differentiated adenocarcinoma, poorly differentiated SCC, high-grade neuroendocrine carcinoma, and large cell lymphoma. Further IHC analysis required for tumor characterizationIIB (T2a, N1)
TP53
412.052.8——Disease-free
Patient #047RealWell-differentiated adenocarcinoma, no LVI, no STATS, stage IA3 (T1c, N0, Mx)IA3 (T1c, N0)
EGFR Exon 19 DelTP53
2.58.961.4——Disease-free
Patient #048RealWell-differentiated adenocarcinoma, mucinous type, no LVI, no STATSIIB (T3, N0)
Not testedKRAS G12VGNAS
4.72.631.6——Stable
Patient #049RealModerately differentiated adenocarcinoma, acinar type, No LVI, no STATSIIIA (T4, N0)
EGFR Exon 19 Del
3.814.0312.7——Partial Response
Patient #050RealEarly-stage well-differentiated adenocarcinoma, no LVI, no STATSIA2 (T1b, N0)
RET
1.21.651.1——Disease-free
Patient #051RealModerately differentiated squamous cell carcinoma, no LVI, no STATSIB (T2a, N0)
TP53
48.051.8——Disease-free
Patient #052RealModerately differentiated adenocarcinoma, acinar type, No LVI, no STATSIA3 (T1c, N0)
EGFR L858RCTNNB1
2.64.3213.3——Watchful Wait
Patient #053RealWell differentiated adenocarcinoma, acinar type stage 1A2, no LVI, no STATSIA2 (T1b, N0)
ALK fusion
1.78.61.8——Disease-free
Patient #054RealNo granuloma, atypical cells or malignancy is seenNA
Not tested
1.84.131.7——N/A
Patient #055RealPoorly differentiated adenocarcinoma, stage IA2, no LVI, no STATSIA2 (T1b, N0)
ROS1
2.0413.851——Stable
Patient #056RealWell-differentiated adenocarcinoma, no LVI, no STATSIA3 (T1c, N0)
EGFR L861Q
2.72.35.3——Watchful Wait
Patient #057RealWell-differentiated adenocarcinoma, no LVI, no STATS, no LN involvementIA3 (T1c, N0)
EGFR Exon 19 DelTP53
2.46.231.9——Disease-free
Patient #058RealModerately differentiated adenocarcinoma, no LVI, no STATS, no LN involvementIB (T2a, N0)
EGFR Exon 19 Del
3.75.872——Disease-free
Patient #059RealWell-differentiated adenocarcinoma, acinar type, no LVI, no STATS, no LN involvementIB (T2a, N0)
EGFR Exon 19 Del
3.72.682.4——Disease-free
Patient #060RealWell-differentiated adenocarcinoma, acinar type, no LVI, no STATS, no LN involvementIB (T2a, N0)
EGFR L858R
3.933——Watchful Wait
Patient #061RealModerately differentiated adenosquamous adenocarcinoma, no LVI, no STATS, no LN involvementIIB (T2a, N1)
Not tested
420.478.1——Disease-free
Patient #062RealModerately differentiated adenocarcinoma, acinar type, no LVI, no STATS, no LN involvementIIB (T3, N0)
EGFR L858RTP53
3.610.148.8——Disease-free
SYN-001MockAdenocarcinoma: SolidIB (T2a, N0)
KRAS G12V
3.06.435.567%NEStable
SYN-002MockAdenocarcinoma: AcinarIIB (T2a, N1)
Not tested
5.08.746.898%PRStable
SYN-003MockAdenocarcinoma: Mucinous adenocarcinomaIIIB (T3, N2)
Not tested
6.16.0732.029%PRProgression
SYN-004MockAdenocarcinoma: AcinarIVB (T4, N3, M1c)
Not tested
8.411.5533.560%PRPartial Response
SYN-005MockAdenocarcinoma: Mucinous adenocarcinomaIA2 (T1b, N0)
Not tested
2.57.682.990%PDDisease-free
SYN-006MockNecrotizing granulomatous inflammation, AFB positiveNA
Not tested
2.0NANormal0%NEN/A
SYN-007MockAdenocarcinoma: Mucinous adenocarcinomaIIIA (T2a, N2)
Not tested
5.57.6322.252%PDDisease-free
SYN-008MockNecrotizing granulomatous inflammation, AFB positiveNA
Not tested
1.9NANormal0%NEN/A
SYN-009MockAdenocarcinoma: Mucinous adenocarcinomaIVB (T4, N3, M1c)
Not tested
7.216.90201.714%CRDeceased
SYN-010MockNecrotizing granulomatous inflammation, AFB positiveNA
Not tested
1.70.68Normal0%NEN/A
SYN-011MockAdenocarcinoma: Acinar, ALK rearrangedIIB (T3, N0)
ALK fusion
3.95.563.022%CRStable
SYN-012MockNecrotizing granulomatous inflammation, AFB positiveNA
Not tested
1.6NANormal0%NEN/A
SYN-013MockAdenocarcinoma: Acinar, ALK rearrangedIVA (T4, N3, M1a)
ALK fusion
6.218.78136.311%CRStable
SYN-014MockBenign hamartoma, no granuloma or atypical cells seenNA
Not tested
1.51.62Normal0%NEN/A
SYN-015MockAdenocarcinoma: Acinar, ALK rearrangedIB (T2a, N0)
ALK fusion
1.56.818.329%NEStable
SYN-016MockBenign hamartoma, no granuloma or atypical cells seenNA
Not tested
1.4NANormal0%NEN/A
SYN-017MockAdenocarcinoma: Acinar, ALK rearrangedIIIB (T3, N2)
ALK fusion
3.86.5512.618%PRDisease-free
SYN-018MockBenign hamartoma, no granuloma or atypical cells seenNA
Not tested
1.2NANormal0%NEN/A
SYN-019MockAdenocarcinoma: Acinar, ALK rearrangedIA2 (T1b, N0)
ALK fusion
1.18.065.76%SDWatchful Wait
SYN-020MockAdenocarcinoma: AcinarIIA (T2b, N0)
EGFR L858RTP53
2.710.387.115%PRDisease-free
SYN-021MockAdenocarcinoma: Acinar, ALK rearrangedIIIA (T2a, N2)
ALK fusion
3.18.1132.825%SDStable
SYN-022MockAdenocarcinoma: AcinarIIIC (T4, N3)
EGFR L858R
7.011.007.94%PRProgression
SYN-023MockAdenocarcinoma: Acinar, ALK rearrangedIVB (T4, N3, M1c)
ALK fusion
9.717.4772.813%PRDeceased
SYN-024MockAdenocarcinoma: AcinarIA3 (T1c, N0)
EGFR L858RTP53
3.13.634.522%PRDisease-free
SYN-025MockAdenocarcinoma: Acinar, ALK rearrangedIIB (T3, N0)
ALK fusion
5.15.945.82%PRStable
SYN-026MockAdenocarcinoma: AcinarIIIA (T4, N0)
EGFR L858R
6.312.5728.111%NEStable
SYN-027MockAdenocarcinoma: Solid with signet ring features, ROS1 rearrangedIVA (T4, N3, M1a)
ROS1
8.719.35207.420%PRPartial Response
SYN-028MockAdenocarcinoma: AcinarIA1 (T1a, N0)
EGFR L858R
2.74.881.829%NEDisease-free
SYN-029MockAdenocarcinoma: Solid with signet ring features, ROS1 rearrangedIB (T2a, N0)
ROS1
2.67.193.28%CRStable
SYN-030MockAdenocarcinoma: AcinarIIB (T2a, N1)
EGFR L858RTP53
4.59.514.518%CRProgression
SYN-031MockAdenocarcinoma: Solid with signet ring features, ROS1 rearrangedIIIB (T3, N2)
ROS1
5.57.0323.327%PRProgression
SYN-032MockAdenocarcinoma: AcinarIVB (T4, N3, M1c)
EGFR L858RTP53
7.512.70175.76%PRPartial Response
SYN-033MockAdenocarcinoma: Solid with signet ring features, ROS1 rearrangedIA2 (T1b, N0)
ROS1
2.28.458.615%CRDisease-free
SYN-034MockAdenocarcinoma: AcinarIIA (T2b, N0)
EGFR L858RTP53
4.010.761.925%CRStable
SYN-035MockAdenocarcinoma: Acinar, RET fusionIIIA (T2a, N2)
RET
4.88.5913.54%SDProgression
SYN-036MockAdenocarcinoma: AcinarIIIC (T4, N3)
EGFR L858RTP53
4.711.4818.513%PRDisease-free
SYN-037MockAdenocarcinoma: Acinar, RET fusionIVB (T4, N3, M1c)
RET
6.318.05143.922%PDDeceased
SYN-038MockAdenocarcinoma: AcinarIA3 (T1c, N0)
EGFR L858R
1.64.017.32%PRDisease-free
SYN-039MockAdenocarcinoma: Acinar, RET fusionIIB (T3, N0)
RET
3.46.338.711%PRStable
SYN-040MockAdenocarcinoma: AcinarIIIA (T4, N0)
EGFR L858RTP53
4.013.058.720%CRDisease-free
SYN-041MockAdenocarcinoma: Acinar, RET fusionIVA (T4, N3, M1a)
RET
5.319.9378.629%SDStable
SYN-042MockAdenocarcinoma: AcinarIA1 (T1a, N0)
EGFR L858R
1.25.264.79%PRDisease-free
SYN-043MockAdenocarcinoma: Acinar, RET fusionIB (T2a, N0)
RET
1.17.586.018%CRStable
SYN-044MockAdenocarcinoma: Acinar and papillaryIIB (T2a, N1)
EGFR Exon 19 Del
2.89.897.427%NEDisease-free
SYN-045MockAdenocarcinoma: Solid, NTRK rearrangedIIIB (T3, N2)
Not tested
3.27.5134.022%PRStable
SYN-046MockAdenocarcinoma: Acinar and papillaryIVB (T4, N3, M1c)
EGFR Exon 19 Del
4.013.2846.816%SDPartial Response
SYN-047MockAdenocarcinoma: Solid, NTRK rearrangedIA2 (T1b, N0)
Not tested
3.28.833.484%CRDisease-free
SYN-048MockAdenocarcinoma: Acinar and papillaryIIA (T2b, N0)
EGFR Exon 19 Del
5.33.144.84%CRDisease-free
SYN-049MockAdenocarcinoma: Solid, NTRK rearrangedIIIA (T2a, N2)
Not tested
6.59.0724.245%SDPartial Response
SYN-050MockAdenocarcinoma: Acinar and papillaryIIIC (T4, N3)
EGFR Exon 19 Del
6.411.9629.222%PRStable
SYN-051MockAdenocarcinoma: Sarcomatoid features (MET ex14)IVB (T4, N3, M1c)
Not tested
8.818.62215.17%PRProgression
SYN-052MockAdenocarcinoma: Acinar and papillaryIA3 (T1c, N0)
EGFR Exon 19 Del
2.74.402.111%CRDisease-free
SYN-053MockAdenocarcinoma: Sarcomatoid features (MET ex14)IIB (T3, N0)
Not tested
4.66.713.568%CRWatchful Wait
SYN-054MockAdenocarcinoma: Acinar and papillaryIIIA (T4, N0)
EGFR Exon 19 Del
5.713.5319.429%CRStable
SYN-055MockAdenocarcinoma: Sarcomatoid features (MET ex14)IVA (T4, N3, M1a)
Not tested
7.88.50149.730%SDPartial Response
SYN-056MockAdenocarcinoma: Acinar and papillaryIA1 (T1a, N0)
EGFR Exon 19 Del
2.35.657.518%PRDisease-free
SYN-057MockAdenocarcinoma: Sarcomatoid features (MET ex14)IB (T2a, N0)
Not tested
2.27.968.992%PRStable
SYN-058MockAdenocarcinoma: Acinar and papillaryIIB (T2a, N1)
EGFR Exon 19 Del
4.010.272.26%SDDisease-free
SYN-059MockAdenocarcinoma: AcinarIIIB (T3, N2)
Not tested
4.97.9914.653%PRDisease-free
SYN-060MockAdenocarcinoma: Acinar and papillaryIVB (T4, N3, M1c)
EGFR Exon 19 Del
6.513.85117.925%CRStable
SYN-061MockAdenocarcinoma: AcinarIA2 (T1b, N0)
Not tested
1.89.216.315%CRDisease-free
SYN-062MockAdenocarcinoma: Acinar and papillaryIIA (T2b, N0)
EGFR Exon 19 Del
3.53.537.613%NEDisease-free
SYN-063MockAdenocarcinoma: AcinarIIIA (T2a, N2)
Not tested
4.29.5534.876%SDDisease-free
SYN-064MockAdenocarcinoma: Acinar and papillaryIIIC (T4, N3)
EGFR Exon 19 Del
4.012.449.92%PRDisease-free
SYN-065MockAdenocarcinoma: Mixed papillary and acinar patterns (HER2 exon 20)IA1 (T1a, N0)
ERBB2 Exon 20
1.310.473.638%CRDisease-free
SYN-066MockAdenocarcinoma: Acinar and papillaryIA3 (T1c, N0)
EGFR Exon 19 Del
1.24.785.020%CRDisease-free
SYN-067MockAdenocarcinoma: Mixed papillary and acinar patterns (HER2 exon 20)IIB (T3, N0)
ERBB2 Exon 20
2.97.096.399%NEDisease-free
SYN-068MockPoorly differentiated NSCLC adenocarcinoma, EGFR Exon 20 insertionIIIA (T4, N0)
EGFR Exon 20 InsTP53
3.414.0130.19%NEStable
SYN-069MockAdenocarcinoma: Mixed papillary and acinar patterns (HER2 exon 20)IVA (T4, N3, M1a)
ERBB2 Exon 20
4.39.0820.861%PRPartial Response
SYN-070MockPoorly differentiated NSCLC adenocarcinoma, EGFR Exon 20 insertionIA1 (T1a, N0)
EGFR Exon 20 InsTP53
0.86.032.427%PRDisease-free
SYN-071MockAdenocarcinoma: Acinar, HER2 amplifiedIB (T2a, N0)
ERBB2 Exon 20
3.28.353.723%CRDisease-free
SYN-072MockPoorly differentiated NSCLC adenocarcinoma, EGFR Exon 20 insertionIIB (T2a, N1)
EGFR Exon 20 Ins
5.310.665.116%SDDisease-free
SYN-073MockAdenocarcinoma: Acinar, HER2 amplifiedIIIB (T3, N2)
ERBB2 Exon 20
6.58.4625.384%PRPartial Response
SYN-074MockPoorly differentiated NSCLC adenocarcinoma, EGFR Exon 20 insertionIVB (T4, N3, M1c)
EGFR Exon 20 InsTP53
9.114.43189.04%SDPartial Response
SYN-075MockAdenocarcinoma: Acinar, HER2 amplifiedIA2 (T1b, N0)
ERBB2 Exon 20
2.89.601.146%PRDisease-free
SYN-076MockPoorly differentiated NSCLC adenocarcinoma, EGFR Exon 20 insertionIIA (T2b, N0)
EGFR Exon 20 Ins
4.83.912.523%SDProgression
SYN-077MockAdenocarcinoma: Solid, poorly differentiated, KEAP1/STK11 co-mut (immune-cold)IIIA (T2a, N2)
KRAS G12CTP53
5.910.0315.57%PDStable
SYN-078MockPoorly differentiated NSCLC adenocarcinoma, EGFR Exon 20 insertionIIIC (T4, N3)
EGFR Exon 20 InsTP53
5.712.9220.511%PRStable
SYN-079MockAdenocarcinoma: Solid, poorly differentiated, KEAP1/STK11 co-mut (immune-cold)IA1 (T1a, N0)
KRAS G12CTP53
2.410.856.569%CRDisease-free
SYN-080MockAdenocarcinoma: AcinarIA3 (T1c, N0)
EGFR L861Q
2.35.167.80%NEDisease-free